Kristin Abate, Chief Accounting Officer at Karyopharm Therapeutics Inc. (KPTI), sold 50 shares at $7.03 ($352) on 2026-01-28, disclosed to the SEC on 2026-01-29.
Open-market sale of $352 KPTI by Chief Accounting Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| KPTI | SELL | 2026-05-15 | $504 | — | Filing → |
| KPTI | SELL | 2026-03-03 | $5K | — | Filing → |
| KPTI | SELL | 2026-01-22 | $2K | — | Filing → |